Starting dose
On the brand labels, semaglutide starts at 0.25 mg weekly and tirzepatide at 2.5 mg weekly. Starting doses are for getting used to the medicine.
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your brain you're full, slows stomach emptying, and stabilizes blood sugar. The medication amplifies this natural signal so the constant fight against hunger and cravings finally lets up.
The curve is an illustration of how GLP-1 loss tends to build while diet alone plateaus, not a trial result. The measured numbers for each molecule come from the brand-name trials below.
Average body-weight change at 72 weeks in SURMOUNT-5, an open-label trial of brand-name Zepbound vs Wegovy in 751 adults with obesity (Aronne et al., NEJM 2025). Compounded versions were not studied.
Both molecules start low and step up about every 4 weeks, because the FDA labels say gradual escalation reduces digestive side effects. Your provider sets your own pace.
On the brand labels, semaglutide starts at 0.25 mg weekly and tirzepatide at 2.5 mg weekly. Starting doses are for getting used to the medicine.
Doses rise in steps of at least 4 weeks: semaglutide 0.5, 1 and 1.7 mg; tirzepatide in 2.5 mg steps.
Label maintenance is 1.7 or 2.4 mg weekly for semaglutide and 5, 10 or 15 mg for tirzepatide, chosen on response and tolerability.
Message your care team about side effects or a plateau; your provider can hold, lower or raise the dose.
Quick health questionnaire — about 5 minutes. We use it to match you to the right medication and dose.
A US-licensed clinician reviews your full profile and either prescribes or comes back with a question.
Your medication arrives free of charge with everything you need to start. Provider support is included.
Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GLP-1 and GIP. Brand semaglutide for weight is Wegovy; brand tirzepatide for weight is Zepbound. Both are once-weekly injections with the same boxed warning about thyroid C-cell tumors on their labels.
In their main trials, Wegovy 2.4 mg produced an average 14.9% loss at 68 weeks (STEP 1) and Zepbound 5 to 15 mg produced 15.0% to 20.9% at 72 weeks (SURMOUNT-1). In the only head-to-head trial, SURMOUNT-5, tirzepatide averaged 20.2% vs 13.7% for semaglutide. These are results for the brand-name drugs, not for compounded versions.
Compounded drugs are prepared by a licensed pharmacy for an individual prescription. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, and it states that compounded semaglutide and tirzepatide are not FDA-approved. That is why Gala never borrows brand trial numbers for its compounded medication, and why a licensed provider reviews your full history before prescribing.
You take a short online assessment, and a licensed provider reviews it and prescribes only if a GLP-1 is appropriate for you. The medication comes from licensed compounding pharmacies and ships free. All doses are included in the plan price, so stepping up from a starting dose to maintenance does not change what you pay, and your care team stays on messaging for side effects and dose questions.
At Gala, compounded semaglutide starts at $69 per month and compounded tirzepatide at $99 per month, on the annual plan, billed once a year. All doses are included, and no insurance is needed. GLP-1 cost without insurance Does the GLP-1 price go up with the dose?
Neither is better for everyone. In SURMOUNT-5, brand-name tirzepatide (Zepbound) produced more average weight loss than brand-name semaglutide (Wegovy) at 72 weeks. Compounded versions were not trialed. Your provider weighs your history, side effects and goals before choosing.
Doses start low and rise about every 4 weeks, so the full effect comes after the step-ups. In the brand trials, weight was measured at 68 weeks for Wegovy and 72 weeks for Zepbound. Results vary by person. How long does a GLP-1 take to work?
The most common side effects on the labels are nausea, diarrhea, vomiting and constipation, mostly during dose escalation. Your provider adjusts your dose to keep them manageable.
Compounded GLP-1 is made by licensed compounding pharmacies and is not FDA-approved; the FDA does not review compounded drugs before they are sold. A licensed provider reviews your full medical history before prescribing and follows you during treatment.
The labels differ by molecule: Wegovy's says to stop semaglutide at least 2 months before a planned pregnancy, and Zepbound's says to stop tirzepatide once a pregnancy is recognized. Tell your provider before you start trying. Planning a pregnancy while on a GLP-1
Often, yes. A licensed provider reviews your online assessment and messages you with questions. Some states or health histories require a live video visit, and your provider will tell you if yours does. Do you need a video visit?
This page is general information, not medical advice. A licensed provider decides whether a treatment is right for you.